Phaseline

Companies › OSE Immunotherapeutics

OSE Immunotherapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OSE2101
peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an
TP53, ERBB2, CEA, MAGEA2, MAGEA3Phase 3Patients With Non-Small Cell Lung Cancer; Solid Advanced TumorDec 2027
OSE-279
PD-1 blocking monoclonal antibody
PDCD1Phase 1Solid Advanced TumorDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06472245OSE2101Phase 3Patients With Non-Small Cell Lung CancerOncologyDec 2027
NCT05751798OSE-279Phase 1Solid Advanced TumorOncologyDec 2029
NCT05751798OSE2101Phase 1Solid Advanced TumorOncologyDec 2029

Targets

PDCD1 (1) TP53 (1) ERBB2 (1) CEA (1) MAGEA2 (1) MAGEA3 (1)

Companies with the same targets

Beijing Biotech Shenyang Sunshine Pharmaceutical Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Akeso Roche Innovent Biologics (Suzhou) Jiangsu HengRui Medicine AstraZeneca Pfizer

Companies built like this

Advenchen Laboratories Advenchen Laboratories Nanjing Nuvalent Clarity Pharmaceuticals TYK Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.